Premium
Association of I/D ACE polymorphisms with hormonal status and oxidative stress in Mexican Mestizo women
Author(s) -
Lugo Gabriela,
HernandezCaballero Marta,
NicolásFranco Ricardo,
OcharanHernández Esther,
JiménezZamarripa Carlos,
CalzadaFrías Jesús,
LinarezPérez Luz,
CalzadaMendoza Claudia
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.lb211
Subject(s) - malondialdehyde , oxidative stress , menopause , medicine , hormone , lipid profile , endocrinology , genotype , physiology , diabetes mellitus , biology , genetics , gene
OBJECTIVE Analyze the association between the presence of I/D ACE variants with hormonal status and oxidative stress in Mexican Mestizo women. METHODS In this study were included 38 healthy women and divided into two groups (pre‐menopausal or postmenopausal), to which a) menopause was corroborated by clinical evaluation and hormonal profile; b) polymorphisms were identified by real‐time PCR, sense oligonucleotide (5′‐CTG GAG ACC ACT CCC ATC CTT TCT‐3′) and antisense oligonucleotide (5′‐GTG GCC ATC AT ACA TTC GTC AGA‐3′); c) malondialdehyde was identified as a marker of lipid damage oxidative stress. RESULTS The women included were classified according their estrogenic status (premenopausal or postmenopausal), which was corroborated by medical history and hormonal profile. With respect malondialdehyde and glucose levels we found that were significantly higher in post‐menopausal (Mann‐Whitney U Statistic, p <0.001). However, in each group, oxidative stress and blood glucose were not associated with genotypes. CONCLUSIONS The I/D ACE genotypes were not associated with damage to lipids or with hyperglycemia observed in postmenopausal but it could participate associated with other risk factors. Before might due to the analyzed women were healthy, right now we are studying the association between I/D ACE genotypes and response to tibolona therapy in hypertenses postmenopausal.